The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Anaplastic lymphoma kinase-rearranged lung cancer is associated with significant response
to crizotinib. However, resistance to crizotinib typically develops within 1-2 years. Preclinical …

Several targetable genetic alterations have been found in lung cancer, predominantly in
adenocarcinomas, which have led to important therapeutic advancements with the advent of …

Patients with non-small cell lung cancer, especially adenocarcinomas, harbour at least one
oncogenic driver mutation that can potentially be a target for therapy. Treatments of these …

Histologic changes can be involved in resistance to anticancer drugs. Transformation to
small cell lung carcinoma (SCLC) following treatment with EGFR tyrosine kinase inhibitors …

Objectives To review the outcomes of treatment in patients with pulmonary sarcomatoid
carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results …

The evolution of personalised medicine in lung cancer has dramatically impacted diagnostic
pathology. Current challenges centre on the growing demands placed on small tissue …

The identification of actionable targets in oncogene-addicted non-small cell lung cancer
(NSCLC) has fueled biomarker-directed strategies, especially in advanced stage disease …

Patients with non-small cell lung cancer (NSCLC) with echinoderm microtubule-associated
protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangements generally respond …